Mogy Joel R Investment Counsel Inc. Has $16 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Mogy Joel R Investment Counsel Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 43.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,684 shares of the company’s stock after purchasing an additional 46,500 shares during the quarter. Novo Nordisk A/S makes up about 1.2% of Mogy Joel R Investment Counsel Inc.’s portfolio, making the stock its 25th largest holding. Mogy Joel R Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $16,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. CNB Bank bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $26,000. Pacific Center for Financial Services raised its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $28,000. Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after buying an additional 141 shares during the last quarter. Finally, Bell Investment Advisors Inc raised its holdings in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO traded up $1.06 on Friday, reaching $126.85. The company had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. The business has a 50 day simple moving average of $126.86 and a 200 day simple moving average of $111.98. The company has a market cap of $569.24 billion, a price-to-earnings ratio of 46.90, a P/E/G ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NVO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.